Literature DB >> 27573928

New Biological Insights in the Immunomodulatory Effects of Mucosal Polybacterial Vaccines in Clinical Practice.

Marta Tejera-Alhambra, Oscar Palomares, Rebeca Perez de Diego, Ignacio Diaz-Lezcano, Silvia Sanchez-Ramon1.   

Abstract

A main focus in healthcare is the active search for alternative strategies to antibiotics, both for prophylactic and therapeutical interventions, due to the accelerated and widespread increase in antibiotic resistance. This problem is more marked for patients with recurrent infections, in which the risk for antibiotic resistance and adverse effects is higher and can be life-threatening. Although antibiotics remain the mainstay of treatment for infectious diseases, prophylactic vaccines via the mucosal route in defined populations of patients with recurrent infections has gained use in recent years. Concomitantly, relevant advances in the formulation and administration of these vaccines driven by an increased knowledge of mucosal immunity have expanded their use, although still in its infancy. These drugs target both the innate and adaptive immune systems, at the actual point of entry of most pathogens. A fascinating new application of the concepts of trained immunity may open novel studies in their potential uses, given the paradoxically simultaneous pro-tolerogenic and boosting effector effects on diverse immune cells for different antigens. Here we delineate an updated review on the immunomodulatory mechanisms of mucosal polybacterial vaccines. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Mucosal immune system; immunomodulation; mucosal bacterial vaccines; recurrent infections

Mesh:

Substances:

Year:  2016        PMID: 27573928     DOI: 10.2174/1381612822666160829143129

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

1.  Human dendritic cells activated with MV130 induce Th1, Th17 and IL-10 responses via RIPK2 and MyD88 signalling pathways.

Authors:  Cristina Cirauqui; Cristina Benito-Villalvilla; Silvia Sánchez-Ramón; Sofía Sirvent; Carmen M Diez-Rivero; Laura Conejero; Paola Brandi; Lourdes Hernández-Cillero; Juliana Lucía Ochoa; Beatriz Pérez-Villamil; David Sancho; José Luis Subiza; Oscar Palomares
Journal:  Eur J Immunol       Date:  2017-09-14       Impact factor: 5.532

Review 2.  Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations.

Authors:  Silvia Sánchez-Ramón; Laura Conejero; Mihai G Netea; David Sancho; Óscar Palomares; José Luis Subiza
Journal:  Front Immunol       Date:  2018-12-17       Impact factor: 7.561

Review 3.  Lessons from Bacillus Calmette-Guérin: Harnessing Trained Immunity for Vaccine Development.

Authors:  Samuel T Pasco; Juan Anguita
Journal:  Cells       Date:  2020-09-16       Impact factor: 6.600

4.  A Combination of Polybacterial MV140 and Candida albicans V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections.

Authors:  Leticia Martin-Cruz; Carmen Sevilla-Ortega; Cristina Benito-Villalvilla; Carmen M Diez-Rivero; Silvia Sanchez-Ramón; José Luis Subiza; Oscar Palomares
Journal:  Front Immunol       Date:  2021-01-21       Impact factor: 7.561

5.  Trained Immunity-Based Vaccine in B Cell Hematological Malignancies With Recurrent Infections: A New Therapeutic Approach.

Authors:  Juliana Ochoa-Grullón; Celina Benavente Cuesta; Ataúlfo González Fernández; Gustavo Cordero Torres; Cristina Pérez López; Ascensión Peña Cortijo; Laura Conejero Hall; Marta Mateo Morales; Antonia Rodríguez de la Peña; Carmen M Díez-Rivero; Edgard Rodríguez de Frías; Kissy Guevara-Hoyer; Miguel Fernández-Arquero; Silvia Sánchez-Ramón
Journal:  Front Immunol       Date:  2021-02-12       Impact factor: 7.561

6.  Involvement of Mesenchymal Stem Cells in Oral Mucosal Bacterial Immunotherapy.

Authors:  Alberto Vázquez; Lidia M Fernández-Sevilla; Eva Jiménez; David Pérez-Cabrera; Rosa Yañez; Jose Luis Subiza; Alberto Varas; Jaris Valencia; Angeles Vicente
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

7.  A Comparison Between Recombinant Listeria GAPDH Proteins and GAPDH Encoding mRNA Conjugated to Lipids as Cross-Reactive Vaccines for Listeria, Mycobacterium, and Streptococcus.

Authors:  Hector Teran-Navarro; David Salcines-Cuevas; Ricardo Calderon-Gonzalez; Raquel Tobes; Jorge Calvo-Montes; Inmaculada Concepción Pérez-Del Molino Bernal; Sonsoles Yañez-Diaz; Manuel Fresno; Carmen Alvarez-Dominguez
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.